uu.seUppsala University Publications
Change search
Link to record
Permanent link

Direct link
BETA
Feresiadou, Amalia
Publications (6 of 6) Show all publications
Feresiadou, A., Nilsson, K., Ingelsson, M., Press, R., Kmezic, I., Nygren, I., . . . Burman, J. (2019). Measurement of sCD27 in the cerebrospinal fluid identifies patients with neuroinflammatory disease. Journal of Neuroimmunology, 332, 31-36
Open this publication in new window or tab >>Measurement of sCD27 in the cerebrospinal fluid identifies patients with neuroinflammatory disease
Show others...
2019 (English)In: Journal of Neuroimmunology, ISSN 0165-5728, E-ISSN 1872-8421, Vol. 332, p. 31-36Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: Laboratory tests to assist in the diagnosis and monitoring of neuroinflammatory diseases are scarce. The soluble form of the CD27 molecule (sCD27) is shed in high concentrations by activated T cells and can be detected in the cerebrospinal fluid. The aim of this study was to investigate whether CSF quantitation of sCD27 could discriminate between inflammatory and non-inflammatory neurological diseases.

METHODS: The concentration of sCD27 was measured using a commercially available ELISA in 803 well-defined subjects from a study cohort comprised of 338 patients with neuroinflammatory disease, 338 with non-inflammatory neurological disease and 127 controls without neurological disease.

RESULTS: The median value of cerebrospinal fluid sCD27 was 64 pg/mL (IQR 0-200) in controls, 58 pg/mL (IQR 0-130) in patients with non-inflammatory disease and 740 pg/mL (IQR 230-1800) in patients with inflammatory disease. The likelihood ratio of having an inflammatory disease was 10 (sensitivity 74% and specificity 93%) if the sCD27 concentration was >250 pg/mL. In patients with a known inflammatory condition, the likelihood ratio of having an infection was 10 (sensitivity 40% and specificity 96%) if the sCD27 concentration was >2500 pg/mL.

CONCLUSIONS: The likelihood of having an inflammatory neurological condition is increased with elevated concentrations of sCD27 in cerebrospinal fluid. Rapid tests of sCD27 should be developed to assist clinicians in diagnosis of neuroinflammatory disease.

National Category
Neurology
Identifiers
urn:nbn:se:uu:diva-381319 (URN)10.1016/j.jneuroim.2019.03.015 (DOI)000470940600004 ()30928869 (PubMedID)
Available from: 2019-04-26 Created: 2019-04-26 Last updated: 2020-01-08
Berntsson, S. G., Kristoffersson, A., Boström, I., Feresiadou, A., Burman, J. & Landtblom, A.-M. (2018). Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden: Outlier or predecessor?. Acta Neurologica Scandinavica, 138(4), 327-331
Open this publication in new window or tab >>Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden: Outlier or predecessor?
Show others...
2018 (English)In: Acta Neurologica Scandinavica, ISSN 0001-6314, E-ISSN 1600-0404, Vol. 138, no 4, p. 327-331Article in journal (Refereed) Published
Abstract [en]

OBJECTIVES: Off-label use of rituximab to treat MS patients in Sweden is high, and the need for long-term safety data may not be met. Our objectives were to assess the rate of rituximab prescription in patients with multiple sclerosis in Sweden and, in addition, to evaluate the safety of rituximab in a single centre for patients with multiple sclerosis.

MATERIAL AND METHODS: Review of the Swedish MS register was performed to study the number of MS patients treated with rituximab during the last 6 years. Investigation also included a retrospective review of medical files in search for possible side effects/adverse events in all adult patients with MS treated with rituximab at Uppsala University Hospital.

RESULTS: Presently, in Sweden the rate of rituximab prescriptions in relation to other annually started of disease- modifying drugs in MS is 53.5%.

CONCLUSIONS: The share of MS patients in Sweden who are treated with rituximab is very high, and also rapidly increasing. Taken into account the off-label use, cases with adverse medical conditions that could possibly be related to rituximab use should be reported thoroughly.

Keywords
adverse events, immunomodulatory drugs, multiple sclerosis, off-label prescription, pharmacotherapy, rituximab side effects
National Category
Neurology
Identifiers
urn:nbn:se:uu:diva-352681 (URN)10.1111/ane.12963 (DOI)000443931400009 ()29797711 (PubMedID)
Available from: 2018-06-07 Created: 2018-06-07 Last updated: 2018-11-06Bibliographically approved
Feresiadou, A., Casar Borota, O., Dragomir, A., Oldfors, C. H., Stålberg, E. & Oldfors, A. (2018). Tubular aggregates in congenital myasthenic syndrome. Neuromuscular Disorders, 28(2), 174-175
Open this publication in new window or tab >>Tubular aggregates in congenital myasthenic syndrome
Show others...
2018 (English)In: Neuromuscular Disorders, ISSN 0960-8966, E-ISSN 1873-2364, Vol. 28, no 2, p. 174-175Article in journal, Editorial material (Other academic) Published
Place, publisher, year, edition, pages
PERGAMON-ELSEVIER SCIENCE LTD, 2018
National Category
Neurology Clinical Laboratory Medicine
Research subject
Pathology
Identifiers
urn:nbn:se:uu:diva-356900 (URN)10.1016/j.nmd.2017.11.009 (DOI)000428487300011 ()29311015 (PubMedID)
Funder
Swedish Research Council, 2012-201
Available from: 2018-08-09 Created: 2018-08-09 Last updated: 2020-01-08Bibliographically approved
Fagius, J., Feresiadou, A., Larsson, E.-M. & Burman, J. (2017). Discontinuation of disease modifying treatments in middle aged multiple sclerosis patients: First line drugs vs natalizumab. Multiple Sclerosis and Related Disorders, 12, 82-87, Article ID S2211-0348(17)30010-X.
Open this publication in new window or tab >>Discontinuation of disease modifying treatments in middle aged multiple sclerosis patients: First line drugs vs natalizumab
2017 (English)In: Multiple Sclerosis and Related Disorders, ISSN 2211-0348, E-ISSN 2211-0356, Vol. 12, p. 82-87, article id S2211-0348(17)30010-XArticle in journal (Refereed) Published
Abstract [en]

BACKGROUND: Several disease-modifying drugs (DMD) are available for the treatment of MS, and most patients with relapsing-remitting disease are currently treated. Data on when and how DMD treatment can be safely discontinued are scarce.

METHODS: Fifteen MS patients, treated with natalizumab for >5 years without clinical and radiological signs of inflammatory disease activity, suspended treatment and were monitored with MRI examinations and clinical follow-up to determine recurrence of disease activity. This group was compared with a retrospectively analysed cohort comprising 55 MS patients treated with first-line DMDs discontinuing therapy in the time period of 1998-2015 after an analogous stable course.

RESULTS: Natalizumab discontinuers were followed for on average 19 months, and follow-up data for 56 months were available for first-line DMD quitters. Two-thirds of natalizumab treated patients experienced recurrent inflammatory disease activity, and one third had recurrence of rebound character. In contrast, 35% of first-line DMD quitters had mild recurrent disease activity, and no one exhibited rebound.

CONCLUSIONS: Withdrawal of a first-line DMD after prolonged treatment in middle-aged MS patients with stable disease appears to be relatively safe, while natalizumab withdrawal in a similar group of patients cannot be safely done without starting alternative therapy.

Keywords
Multiple sclerosis, Natalizumab discontinuation, Rebound, Treatment discontinuation
National Category
Neurology
Identifiers
urn:nbn:se:uu:diva-317425 (URN)10.1016/j.msard.2017.01.009 (DOI)000396908400017 ()28283113 (PubMedID)
Available from: 2017-03-14 Created: 2017-03-14 Last updated: 2018-09-04Bibliographically approved
Fagius, J., Burman, J., Feresiadou, A. & Larsson, E.-M. (2015). Severe relapses and rebound activity after natalizumab discontinuation in MS patients with more than five years of treatment with stable disease course. Paper presented at 31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), OCT 07-10, 2015, Barcelona, SPAIN. Multiple Sclerosis, 21, 297-297
Open this publication in new window or tab >>Severe relapses and rebound activity after natalizumab discontinuation in MS patients with more than five years of treatment with stable disease course
2015 (English)In: Multiple Sclerosis, ISSN 1352-4585, E-ISSN 1477-0970, Vol. 21, p. 297-297Article in journal, Meeting abstract (Other academic) Published
National Category
Neurology
Identifiers
urn:nbn:se:uu:diva-276952 (URN)000365729400509 ()
Conference
31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), OCT 07-10, 2015, Barcelona, SPAIN
Available from: 2016-02-23 Created: 2016-02-16 Last updated: 2017-11-30Bibliographically approved
Feresiadou, A., Eriksson, U., Larsen, H.-C., Raininko, R., Nygren, I. & Melberg, A. (2014). Recurrence of Susac Syndrome following 23 Years of Remission. Case Reports in Neurology, 6(2), 171-175
Open this publication in new window or tab >>Recurrence of Susac Syndrome following 23 Years of Remission
Show others...
2014 (English)In: Case Reports in Neurology, ISSN 1662-680X, E-ISSN 1662-680X, Vol. 6, no 2, p. 171-175Article in journal (Refereed) Published
Abstract [en]

Susac syndrome is an autoimmune microangiopathy affecting the brain, retina and inner ear (cochlea and semicircular canals), leading to encephalopathy, branch retinal artery occlusions (BRAOs) and asymmetric neurosensory hearing loss, respectively. The natural history and long-term prognosis are variable as the disease has been shown to be monophasic and self-limiting, polycyclic or chronic continuous. We describe a 35-year-old woman who presented with a sudden hearing loss in the left ear in the 37th week of her second pregnancy. She subsequently developed BRAO in the right eye 2.5 months after having given birth. MRI findings included round lesions in the corpus callosum which are pathognomonic for Susac syndrome. Previous patient records documented encephalopathy, sudden deafness of the right ear and visual field defects in the left eye at the age of 12, followed by permanent hearing and visual defects. We expand on the variability in the course of Susac syndrome as recurrence may occur after as long as 23 years. Cases of monophasic self-limiting Susac syndrome may in fact turn polycyclic with an interval of more than 2 decades between the bouts of the disease. In these cases, suspecting the development of exacerbation early is important in order to start the treatment promptly.

National Category
Neurology
Identifiers
urn:nbn:se:uu:diva-231588 (URN)10.1159/000362868 (DOI)24987361 (PubMedID)
Available from: 2014-09-09 Created: 2014-09-09 Last updated: 2017-12-05Bibliographically approved
Organisations

Search in DiVA

Show all publications